Improved Syntheses of the mGlu5 Antagonists MMPEP and MTEP Using Sonogashira Cross-Coupling

Autor: Boshuai Mu, Linjing Mu, Roger Schibli, Simon M. Ametamey, Selena Milicevic Sephton

Publikováno v: Pharmaceuticals, Vol 11, Iss 1, p 24 (2018)

The Sonogashira cross-coupling, a key step in the syntheses of the mGlu5 antagonists MMPEP and MTEP, provided an improved three-step method for the preparation of MMPEP in 62% overall yield. Using Spartan molecular modeling kit an explanation for the

Externí odkaz: https://doaj.org/article/a4994ae8d3594021af31130c1afb9254

Ketamine and Ceftriaxone-Induced Alterations in Glutamate Levels Do Not Impact the Specific Binding of Metabotropic Glutamate Receptor Subtype 5 Radioligand [18F]PSS232 in the Rat Brain

Autor: Simon M. Ametamey, Adrienne Müller Herde, Yingfang He, Silvan D. Boss, Linjing Mu, Roger Schibli

Publikováno v: Pharmaceuticals
Volume 11
Issue 3
Pharmaceuticals, 11 (3)
Pharmaceuticals, Vol 11, Iss 3, p 83 (2018)

Several studies showed that [11C]ABP688 binding is altered following drug-induced perturbation of glutamate levels in brains of humans, non-human primates and rats. We evaluated whether the fluorinated derivative [18F]PSS232 can be used to assess met

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe2c6bada319cb874113140cfdbecc6d

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Ketamine and Ceftriaxone-Induced Alterations in Glutamate Levels Do Not Impact the Specific Binding of Metabotropic Glutamate Receptor Subtype 5 Radioligand [ ¹⁸ F]PSS232 in the Rat Brain.

Autor: Müller Herde A; Center for Radiopharmaceutical Sciences of ETH, PSI, and USZ, Department of Chemistry and Applied Biosciences of ETH, 8093 Zurich, Switzerland. adrienne.herde@pharma.ethz.ch., Boss SD; Center for Radiopharmaceutical Sciences of ETH, PSI, and USZ, Department of Chemistry and Applied Biosciences of ETH, 8093 Zurich, Switzerland. silvanboss@hotmail.com., He Y; Center for Radiopharmaceutical Sciences of ETH, PSI, and USZ, Department of Chemistry and Applied Biosciences of ETH, 8093 Zurich, Switzerland. yingfang.he@pharma.ethz.ch., Schibli R; Center for Radiopharmaceutical Sciences of ETH, PSI, and USZ, Department of Chemistry and Applied Biosciences of ETH, 8093 Zurich, Switzerland. roger.schibli@pharma.ethz.ch.; Department of Nuclear Medicine, University Hospital Zurich, 8091 Zurich, Switzerland. roger.schibli@pharma.ethz.ch., Mu L; Center for Radiopharmaceutical Sciences of ETH, PSI, and USZ, Department of Chemistry and Applied Biosciences of ETH, 8093 Zurich, Switzerland. linjing.mu@pharma.ethz.ch.; Department of Nuclear Medicine, University Hospital Zurich, 8091 Zurich, Switzerland. linjing.mu@pharma.ethz.ch., Ametamey SM; Center for Radiopharmaceutical Sciences of ETH, PSI, and USZ, Department of Chemistry and Applied Biosciences of ETH, 8093 Zurich, Switzerland. simon.ametamey@pharma.ethz.ch.

Publikováno v: Pharmaceuticals (Basel, Switzerland) [Pharmaceuticals (Basel)] 2018 Aug 29; Vol. 11 (3). Date of Electronic Publication: 2018 Aug 29.